PFE Stock Analysis & Forecast (2026)

Pfizer Inc. Healthcare Drug Manufacturers - General
$27.56
Current Price
63%
Hold
View Plans
Data refreshed: April 20, 2026

Key Financial Metrics

Market Cap
$156.77B
P/E Ratio (TTM)
20.3x
P/E Forward
9.8x
Revenue Growth
-1.2%
Gross Margin
75.8%
Net Margin
12.4%
Return on Equity
8.9%
Debt/Equity
0.78

AI Analysis Summary

Pfizer Inc. (PFE) is a Healthcare company in the Drug Manufacturers - General industry with a 63% Hold Score. Key strengths include Gross Margin (75.8%), Net Margin (12.4%). Areas to watch: Revenue Growth (-1.2%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Weak Gross Margin: Excellent Net Margin: Good Return on Equity: Low Debt/Equity: Elevated

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

PFE Fundamental Analysis Report
PDF Report Preview
63%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free PFE Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes PFE fundamentals to generate buy/sell signals and Strong Buy Scores.

Why PFE Has a 63% Score

Our AI evaluates Pfizer Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Hold rating:

Recent Catalysts for PFE

Key developments and data points that may impact Pfizer Inc.'s trajectory:

Wall Street consensus target is $28.97 (+5.1% from current price), based on 27 analyst estimates.
Analyst consensus recommendation: Buy.
Institutional ownership at 67.9% — strong smart-money backing.
Dividend yield of 6.24% provides income while you wait for capital appreciation.

PFE vs. Peers

How Pfizer Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
PFE $27.56 $156.77B 20.3x -1.2% 12.4% 8.9%
JNJ $234.18 $564.35B 21.2x 9.9% 21.8%
UNH $324.63 $294.66B 24.5x 12.3% 2.7% 12.5%
MRK $119.07 $294.39B 16.4x 5.0% 28.1% 36.9%
ABBV $208.38 $368.57B 87.6x 10.0% 6.9% 6225.0%

Main Risks for PFE Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Pfizer Inc.:

Revenue Growth (-1.2%)
Low beta of 0.39 suggests limited upside participation in bull markets.
Short interest is elevated with a 3.2-day cover ratio, indicating bearish bets against the stock.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

PFE Balance Sheet & Cash Flow

A snapshot of Pfizer Inc.'s financial health based on the most recent filings:

Total Cash
$13.60B
Total Debt
$67.65B
Current Ratio
1.16
FCF Yield
8.6%
EBITDA
$25.72B
Operating Margin
23.9%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

PFE Valuation Snapshot

Trailing P/E
20.3x
Fairly valued
Forward P/E
9.8x
Earnings growth expected
Price / Book
1.8x
Reasonable
PEG Ratio
13.77
Expensive vs growth
Analyst Target (Mean)
$28.97
Range: $25 – $36
Dividend Yield
6.24%
5Y avg: 4.97%
52-Week Price Range — PFE is trading at 83% of its range
$21.87 (52W Low) $28.75 (52W High)

Is PFE a Buy Right Now?

Based on our AI-powered fundamental analysis, PFE has a Strong Buy Score of 63%, earning a "Hold" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Moderate Buy Signal

Pfizer Inc. shows mixed fundamentals with some strengths and areas to monitor. Positives include Gross Margin (75.8%). Watch for Revenue Growth (-1.2%).

PFE AI Buy & Sell Signals Explained

Our AI analyzes Pfizer Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 63% score:

  • Revenue Growth: -1.2% year-over-year (declining)
  • Gross Margin: 75.8% (strong pricing power)
  • Net Margin: 12.4% (profitable)
  • Return on Equity: 8.9% (positive returns)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for PFE on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With PFE currently trading at $27.56, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when PFE reaches key technical levels.

Earnings & Revenue Outlook

Pfizer Inc. operates in the Healthcare sector, specifically in Drug Manufacturers - General. Understanding earnings trends is crucial for forecasting PFE's trajectory.

Current revenue growth of -1.2% trails the average company.

Visit our Earnings Calendar to track upcoming PFE earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

PFE Stock Forecast (Next 3–12 Months)

Our AI projects PFE's trajectory based on current fundamentals and historical patterns. With a 63% Strong Buy Score, here's what the data suggests:

Mixed Outlook: Pfizer Inc. shows moderate fundamental strength. Revenue growth at -1.2% and warrants monitoring. The stock may trade sideways or experience modest gains depending on execution and market conditions.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if PFE is fairly priced. Here's the current snapshot:

  • Market Capitalization: $156.77B
  • P/E Ratio (TTM): 20.3x (fairly valued)
  • Forward P/E: 9.8x (based on analyst estimates)
  • Debt/Equity: 0.78 (moderate leverage)

Our AI weighs these metrics against growth rates and margin quality to determine if PFE offers compelling risk-adjusted returns at current prices.

Bull Case for PFE

Here's why investors are bullish on Pfizer Inc.:

  • Gross Margin (75.8%)
  • Net Margin (12.4%)

While these positives exist, investors should weigh them against the risks outlined in the bear case below.

Bear Case & Risks for PFE

Every investment carries risk. Here are potential concerns for PFE investors:

  • Revenue Growth (-1.2%)

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

PFE Summary: Pfizer Inc. earns a 63% Hold Score based on AI analysis of fundamental data. Trading at $27.56 with a $156.77B market cap, the stock presents a balanced risk/reward profile for the coming year.

Bull Case: Gross Margin (75.8%), Net Margin (12.4%)

Watch: Revenue Growth (-1.2%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free PFE PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this PFE analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like PFE.

What Are Demand Zones?

Find key support and resistance levels for PFE and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for PFE

Demand Zone Analyzer PFE Live Chart Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

Frequently Asked Questions about PFE

Is PFE a good buy right now?
PFE currently has a Strong Buy Score of 63% (Hold). PFE shows moderate buy signals. The stock has mixed fundamentals worth reviewing in detail. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the PFE stock forecast for 2026?
Our AI forecasts PFE based on current fundamentals: revenue growth of -1.2%, net margin of 12.4%, and P/E of 20.3x. The 63% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for PFE?
View real-time PFE demand zones (support) and supply zones (resistance) on our Demand Zones page. With PFE currently at $27.56, you can see how close the stock is to key technical levels. Subscribe to get alerts when PFE approaches these zones.
How do PFE fundamentals compare to peers?
Pfizer Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 75.8%, ROE 8.9%, Debt/Equity 0.78. The 63% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the PFE analysis PDF report free?
Yes! Your first PFE fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Pfizer Inc.'s market cap and P/E ratio?
Pfizer Inc. (PFE) has a market cap of $156.77B and a trailing P/E ratio of 20.3x (forward P/E: 9.8x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This PFE analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.